Many of the<unk> <unk> es currently employed involved immune system checkpoint inhibition which allow for improvement of T-cell activation towards cancer cells. This boost to the immune system can occur by many mechanisms that encompass the list of "novel"<unk>  agents" described below.
Oncologic therapy related adverse events
Decreased cellular immunity which an cause reactivation or new
Paraneoplastic syndromes
Tuberculosis
Post-surgical complications
Sepsis
Intrathecal drug delivery system complications
Fungal infections